Reporting on science and technology news in Montana

Provided by AGP

Sci-Tech Montana: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Montana.

Press releases published on April 22, 2026

Blue Mountain Acquires CompuCal to Expand European Presence and Deepen Calibration Expertise
Blue Mountain übernimmt CompuCal, um seine Präsenz in Europa weiter auszubauen und seine Kalibrierungskompetenz gezielt zu stärken
Blue Mountain acquiert CompuCal pour renforcer sa présence européenne et son expertise en étalonnage
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
Senttr Launches as Digital Worker Platform for Operational Teams, Replacing Aisentr
Hyve Managed Hosting collaborates with Red Hat to accelerate modernization and reduce customer costs
12Build launches innovations in pre-construction
12Build lanceert vernieuwing in de pre-constructie
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
DataParser Announces Support for Yext Relate
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
Syngenta Deploys Tetra OS to Accelerate Scientific Discovery Through Industrial-Scale Data Automation
SUSE and Industry Leaders Deliver Secure Agentic AI for Infrastructure Management
Switch and SUSE Advance Digital Twin Innovation with NVIDIA
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
Ojemda® approuvé dans l’Union européenne comme première thérapie ciblée pour les enfants atteints de gliome pédiatrique de bas grade (pLGG), en rechute ou réfractaire, indépendamment de l’altération de BRAF

Share us

on your social networks:

Sign up for:

Sci-Tech Montana

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.